TY - JOUR T1 - Results of chemotherapy for pulmonary metastases of carcinoma of the cervix in patients after primary surgical and radiotherapeutic management JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 1056 LP - 1061 DO - 10.1111/j.1525-1438.2007.00879.x VL - 17 IS - 5 AU - G. Panek AU - K. Gawrychowski AU - P. Sobiczewski AU - P. Derlatka AU - A. Danska-Bidzinska AU - L. Gmyrek AU - M. Bidzinski Y1 - 2007/09/01 UR - http://ijgc.bmj.com/content/17/5/1056.abstract N2 - The purpose of this study was to evaluate the results of chemotherapy of pulmonary metastases from invasive carcinoma of the cervix, which were detected after a disease-free period after initial treatment with surgery or radiotherapy. Fifty patients with radiologically proven pulmonary metastases were treated with chemotherapy. All patients received a platinum-5-fluorouracil (PF) program: cisplatin 75 mg/m2 and 5-fluorouracil 800 mg/m2 every 4 weeks. The overall 1- and 3-year survival after PF chemotherapy was 62% and 17.6%, respectively. The progression-free survival at 1 and 3 years was 36.7% and 14.3%, respectively. There were 6 (12%) complete responses and 17 (34%) partial responses. Hematologic tolerance was acceptable. Third degree and fourth degree leukopenia was diagnosed in four (8%) and six (12%) patients, respectively. Three individuals had third degree thrombocytopenia. In the multivariate analysis, the following prognostic factors were associated with poor survival: time to recurrence after primary treatment (P= 0.002), number of lung metastases (P= 0.016), and progression during chemotherapy (P= 0.001). We conclude that PF regimen is a safe and reasonably effective chemotherapy in the management of patients with pulmonary metastases after primary treatment for invasive carcinoma of the cervix who do not qualify for surgical metastasectomy. ER -